Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction

Journal of the American College of Cardiology

Volumn 68, Issue 24, 2016, Pages 2652-2666

  Fattah, Caroline ^a   Nather, Katrin ^a   McCarroll, Charlotte S ^a   Hortigon Vinagre, Maria P ^a   Zamora, Victor ^a   Flores Munoz, Monica ^a,b   McArthur, Lisa ^a   Zentilin, Lorena ^c   Giacca, Mauro ^c   Touyz, Rhian M ^a   Smith, Godfrey L ^a   Loughrey, Christopher M ^a   Nicklin, Stuart A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSIDAD VERACRUZANA   (Mexico)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

adeno associated virus; calcium; inotropy; renin angiotensin system

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSIN[1-9]; CYCLIC AMP DEPENDENT PROTEIN KINASE; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-9); PEPTIDE FRAGMENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CALCIUM CURRENT; CARDIAC MUSCLE CELL; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE SEVERITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; EX VIVO STUDY; FUNCTIONAL ASSESSMENT; GENE THERAPY; HEART CONTRACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE POTENTIAL; HEART OUTPUT; HEART PROTECTION; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INOTROPISM; ISOLATED HEART; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NONHUMAN; PRESSURE MEASUREMENT; PRIORITY JOURNAL; SCAR; SHAM PROCEDURE; SINGLE DRUG DOSE; SUDDEN CARDIAC DEATH; SYSTOLE; SYSTOLIC BLOOD PRESSURE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; HEART VENTRICLE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PHYSIOLOGY;

ANGIOTENSIN I; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HEART VENTRICLES; HUMANS; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; STROKE VOLUME; SYSTOLE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85003844969     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.09.946     Document Type: Article

References (45)

1. 1 Donoghue, M., Hsieh, F., Baronas, E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000), E1–E9.
2. 2 Tipnis, S.R., Hooper, N.M., Hyde, R., Karran, E., Christie, G., Turner, A.J., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275 (2000), 33238–33243.
3. 3 Der Sarkissian, S., Huentelman, M.J., Stewart, J., Katovich, M.J., Raizada, M.K., ACE2: a novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91 (2006), 163–198.
4. 4 Ferreira, A.J., Santos, R.A., Almeida, A.P., Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 38 (2001), 665–668.
5. 5 Grobe, J.L., Mecca, A.P., Mao, H., Katovich, M.J., Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 290 (2006), H2417–H2423.
6. 6 Balingit, P.P., Armstrong, D.G., Reyzelman, A.M., et al. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen 20 (2012), 482–490.
7. 7 Pham, H., Schwartz, B.M., Delmore, J.E., et al. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemother Pharmacol 71 (2013), 965–972.
8. 8 Flores-Munoz, M., Work, L.M., Douglas, K., et al. Angiotensin-(1-9) attenuates cardiac fibrosis via the angiotensin type 2 receptor. Hypertension 59 (2012), 300–307.
9. 9 Ocaranza, M.P., Lavandero, S., Jalil, J.E., et al. Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 28 (2010), 1054–1064.
10. 10 Ocaranza, M.P., Moya, J., Barrientos, V., et al. Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J Hypertens 32 (2014), 771–783.
11. 11 Flores-Munoz, M., Smith, N.J., Haggerty, C., Milligan, G., Nicklin, S.A., Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol 589 (2011), 939–951.
12. 12 Jessup, M., Greenberg, B., Mancini, D., et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124 (2011), 304–313.
13. 13 Flores-Munoz, M., Godinho, B.M., Almalik, A., Nicklin, S.A., Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin type 2 receptor. PLoS One, 7, 2012, e45564.
14. 14 Mercure, C., Yogi, A., Callera, G.E., et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103 (2008), 1319–1326.
15. 15 Methot, D., vanKats, J.P., Lochard, N., Tremblay, F., Silversides, D.W., Reudelhuber, T.L., Development and application of a biological peptide pump for the study of the in vivo actions of angiotensin peptides. Am J Hypertens 14 (2001), 38S–43S.
16. 16 Mano, M., Ippodrino, R., Zentilin, L., Zacchigna, S., Giacca, M., Genome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction. Proc Natl Acad Sci U S A 112 (2015), 11276–11281.
17. 17 Inagaki, K., Fuess, S., Storm, T.A., et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14 (2006), 45–53.
18. 18 Elliott, E.B., Hasumi, H., Otani, N., et al. K201 (JTV-519) alters the spatiotemporal properties of diastolic Ca(2+) release and the associated diastolic contraction during beta-adrenergic stimulation in rat ventricular cardiomyocytes. Basic Res Cardiol 106 (2011), 1009–1022.
19. 19 Bell, R.M., Mocanu, M.M., Yellon, D.M., Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol 50 (2011), 940–950.
20. 20 Trafford, A.W., Diaz, M.E., Sibbring, G.C., Eisner, D.A., Modulation of CICR has no maintained effect on systolic Ca2+: simultaneous measurements of sarcoplasmic reticulum and sarcolemmal Ca2+ fluxes in rat ventricular myocytes. J Physiol 522:Pt 2 (2000), 259–270.
21. 21 Elliott, E.B., Kelly, A., Smith, G.L., Loughrey, C.M., Isolated rabbit working heart function during progressive inhibition of myocardial SERCA activity. Circ Res 110 (2012), 1618–1627.
22. 22 Elliott, E.B., McCarroll, D., Hasumi, H., et al. Trypanosoma brucei cathepsin-L increases arrhythmogenic sarcoplasmic reticulum-mediated calcium release in rat cardiomyocytes. Cardiovasc Res 100 (2013), 325–335.
23. 23 Eisner, D.A., Trafford, A.W., Diaz, M.E., Overend, C.L., O'Neill, S.C., The control of Ca release from the cardiac sarcoplasmic reticulum: regulation versus autoregulation. Cardiovasc Res 38 (1998), 589–604.
24. 24 De Mello, W.C., Intracellular angiotensin (1-7) increases the inward calcium current in cardiomyocytes. On the role of PKA activation. Mol Cell Biochem 407 (2015), 9–16.
25. 25 Kane, C., Couch, L., Terracciano, C.M., Excitation-contraction coupling of human induced pluripotent stem cell-derived cardiomyocytes. Front Cell Dev Biol, 3, 2015, 59.
26. 26 Gehrmann, J., Frantz, S., Maguire, C.T., et al. Electrophysiological characterization of murine myocardial ischemia and infarction. Basic Res Cardiol 96 (2001), 237–250.
27. 27 Lutgens, E., Daemen, M.J., de Muinck, E.D., Debets, J., Leenders, P., Smits, J.F., Chronic myocardial infarction in the mouse: cardiac structural and functional changes. Cardiovasc Res 41 (1999), 586–593.
28. 28 Figueras, J., Alcalde, O., Barrabes, J.A., et al. Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation 118 (2008), 2783–2789.
29. 29 Nian, M., Lee, P., Khaper, N., Liu, P., Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94 (2004), 1543–1553.
30. 30 Yabluchanskiy, A., Li, Y., Chilton, R.J., Lindsey, M.L., Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets 14 (2013), 276–286.
31. 31 Arsic, N., Zentilin, L., Zacchigna, S., et al. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 7 (2003), 450–459.
32. 32 Eulalio, A., Mano, M., Dal Ferro, M., et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492 (2012), 376–381.
33. 33 Lovric, J., Mano, M., Zentilin, L., Eulalio, A., Zacchigna, S., Giacca, M., Terminal differentiation of cardiac and skeletal myocytes induces permissivity to AAV transduction by relieving inhibition imposed by DNA damage response proteins. Mol Ther 20 (2012), 2087–2097.
34. 34 Grobe, J.L., Der Sarkissian, S., Stewart, J.M., Meszaros, J.G., Raizada, M.K., Katovich, M.J., ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) 113 (2007), 357–364.
35. 35 Iwata, M., Cowling, R.T., Gurantz, D., et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289 (2005), H2356–H2363.
36. 36 Gregorevic, P., Blankinship, M.J., Allen, J.M., et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10 (2004), 828–834.
37. 37 van Kats, J.P., Methot, D., Paradis, P., Silversides, D.W., Reudelhuber, T.L., Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice. Direct and indirect effects of angiotensin II on the heart. J Biol Chem 276 (2001), 44012–44017.
38. 38 Wang, Y., Qian, C., Roks, A.J., et al. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail 3 (2010), 286–293.
39. 39 Qi, Y., Shenoy, V., Wong, F., et al. Lentiviral mediated overexpression of Angiotensin-(1-7) attenuated ischemia-induced cardiac pathophysiology. Exp Physiol 96 (2011), 863–874.
40. 40 Nio, Y., Matsubara, H., Murasawa, S., Kanasaki, M., Inada, M., Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95 (1995), 46–54.
41. 41 Kaschina, E., Grzesiak, A., Li, J., et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?. Circulation 118 (2008), 2523–2532.
42. 42 Zhao, W., Zhao, T., Chen, Y., Sun, Y., Angiotensin 1-7 promotes cardiac angiogenesis following infarction. Curr Vasc Pharmacol 13 (2015), 37–42.
43. 43 De Mello, W.C., Monterrubio, J., Intracellular and extracellular angiotensin II enhance the L-type calcium current in the failing heart. Hypertension 44 (2004), 360–364.
44. 44 Petroff, M.G., Aiello, E.A., Palomeque, J., Salas, M.A., Mattiazzi, A., Subcellular mechanisms of the positive inotropic effect of angiotensin II in cat myocardium. J Physiol 529:Pt 1 (2000), 189–203.
45. 45 Kamp, T.J., Hell, J.W., Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res 87 (2000), 1095–1102.